Serina director granted options on 92,000 shares

Serina Therapeutics, Inc. reported that director Simba Gill received a grant of stock options.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported that director Simba Gill received a grant of stock options. On 02/03/2026, he was awarded an option to acquire 92,000 shares of common stock at an exercise price of $2.76 per share, expiring on 02/03/2036.

According to the vesting terms, 12/48ths of the option shares vest twelve months after the vesting commencement date, with the remaining shares vesting in equal 1/48th monthly installments until fully vested, unless the option is earlier terminated under the option agreement.

Insider Trade Summary

Grant/Award: 92,000 shares

Grant/Award 1 txn

Insider GILL SIMBA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	92,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 92,000 contracts (Direct)

Footnotes (1)

1. F1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Serina Therapeutics (SER) disclose in this Form 4?

Serina Therapeutics disclosed that director Simba Gill received a stock option grant. On 02/03/2026, he was awarded options covering 92,000 shares of common stock at a $2.76 exercise price, with the award reported as directly owned following the transaction.

How many Serina Therapeutics (SER) shares are covered by Simba Gill’s new option?

The option grant covers 92,000 shares of Serina Therapeutics common stock. These shares are underlying a single stock option award, with all 92,000 shares reported as beneficially owned through the derivative security following the 02/03/2026 transaction.

What is the exercise price and term of Simba Gill’s Serina Therapeutics stock option?

The stock option has a $2.76 per share exercise price and expires on 02/03/2036. It is a right to buy Serina Therapeutics common stock, providing a long-dated incentive aligned with the company’s share price performance over that period.

How do Simba Gill’s Serina Therapeutics (SER) options vest over time?

The options vest based on a time schedule. Twelve forty-eighths (12/48ths) of the shares vest twelve months after the vesting commencement date, then one forty-eighth (1/48th) vests monthly on the same calendar day until all shares are fully vested, subject to earlier termination.

Is Simba Gill’s Serina Therapeutics option grant classified as a buy or a grant?

The transaction is classified as a grant or award, not an open-market purchase. It is coded as an acquisition (code A) of a derivative security, with a transaction price of $0 and a separate $2.76 exercise price for buying common shares later.

What role does Simba Gill hold at Serina Therapeutics (SER) in this filing?

Simba Gill is identified as a director of Serina Therapeutics in the filing. The Form 4 shows the option grant as a director-level equity award, with the ownership of the derivative security reported as direct rather than through an indirect entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 08:24 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILL SIMBA

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.76	02/03/2026		A		92,000		(1)	02/03/2036	Common Stock	92,000	$0	92,000	D

Explanation of Responses:

1. Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested.

Remarks:

	/s/ Simba Gill	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.